Clinical researchers at Nationwide Children's and The Ohio State University are committed to identifying new approaches for the prevention, diagnosis and treatment of childhood diseases, taking research discoveries from the lab to the patient's bedside.
To see current Ophthalmology clinical studies being conducted at Nationwide Children's Hospital and The Ohio State University, search the options below.
What is convergence insufficiency?
Convergence insufficiency (CI) affects about 5 out of every 100 people. CI is an eye-teaming problem in which the eyes have a strong tendency to drift outward when reading or doing work up close. If the eyes drift out, the person may see double. To avoid seeing double, a person with CI must use extra effort to make the eyes turn back in. This extra effort can lead to annoying symptoms that can interfere with the ability to read and work comfortably up close.
Symptoms often associated with CI:
Eye strain and headaches
Inability to concentrate
Short attention span
Frequent loss of place
Trouble remembering what was read
The need to re-read the same line of words
What is the purpose of the CITT?
The CITT-ART was designed to find out whether therapy for CI improves reading and attention. Children with CI have many more symptoms when reading and show worse attention than children without CI. We know that CI therapy improves these symptoms and we have some early evidence that treatment also results in improvements in reading and attention.
However, to know for sure, we need to study this question in a larger group of children, and some children need to receive a harmless control therapy that is not designed to treat convergence insufficiency.
What will happen during the study?
If you agree to have your child take part in the study, a computer program will determine whether your child will receive active or control therapy. This is similar to flipping a coin. Two of every three children will receive the active therapy. Children who receive the control therapy and don’t get better will be given the active treatment.
The study involves standard tests and treatments which have the same risks as receiving treatment outside the study. No long-term problems are expected. The only known risk is that your child may continue to have eyestrain/headaches.
To allow your child to take part in the study, you must be willing to bring your child to The Ohio State University’s College of Optometry for the following tests and sessions:
Initial testing to see if your child is eligible.
Initial tests of reading and attention.
Weekly therapy sessions for 16 weeks in a row.
Follow-up visits to check your child’s vision, attention and reading about one week and one year after completing the therapy.
You will also need to ensure that your child performs the prescribed home therapy.
Who can I contact for more information?
If you have questions or would like your child to take part in this study, please contact Dr. Marjean Kulp at Kulp.email@example.com or 614-688-3336. For more information online, you can visit www.citt-art.com.
What is the purpose of this study?
The purpose of BLINK is to determine whether soft bifocal contact lenses (typically used to help people older than 40 see up close) slow the progression of nearsightedness (difficulty seeing far away).
Who can participate in this study?
Children ages 7-11 years old
Children who are nearsighted
Children in good general health without problems that may affect contact lens wear
Additional screening questions will be asked by phone or email
What will happen during the study?
The study involves nine visits over a three-year period. Each child who participates will be randomly assigned to wear one of three contact lenses being used in the study: a spherical (regular) contact lens or one of two bifocal contact lenses.
Benefits during study participation include free eye care, contact lenses, contact lens solutions and eye glasses (if frame allowance is not exceeded).
How do I find out if my child is eligible?
To get more information and to see if your child might be eligible, contact Jill Myers, Clinic Coordinator, at 614-292-0200 or firstname.lastname@example.org, or visit http://blinkstudy.org/. You will be asked to answer some questions about your child’s vision and general health.
Purpose of study:
The purpose of this study is to treat amblyopia that has not responded to treatments in the past (including patching and eye drops).
Who can participate:
Children 7 to 12 years of age
What will happen during the study:
Amblyopia is usually treated with a patch or with eye drops in the good eye; forcing the child to use the weak eye. When this treatment does not cure the amblyopia, some doctors have used a drug called levodopa along with patching of the good eye to treat amblyopia. Levodopa is changed in the body to a chemical called dopamine. Dopamine is thought to have a role in how we see. It works both in the eye and in the brain. It is thought that increasing the dopamine by giving levodopa might improve vision in amblyopia. Levodopa is taken in a capsule by mouth. This study will see if taking levodopa while wearing a patch over the good eye for 2 hours/day can make amblyopia better. It will compare the levodopa group with a smaller group using placebo.
Who to contact:
Study Coordinators Amy Wagner (614.224.6222) and Rae Fellows (614.722.4080)